Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity

Translational Oncology

Volumn 6, Issue 1, 2013, Pages 25-32

  Kassab, Elias ^a   Darwish, Manal ^a   Timsah, Zahra ^a   Liu, ShiHui ^b   Leppla, Stephen H ^b   Frankel, Arthur E ^c   Abi Habib, Ralph J ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1, 4 DIAMINO 1, 4 BIS (2 AMINOPHENYLTHIO) 2, 3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTHRAX TOXIN; CASPASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION;

EID: 84874680158     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12313     Document Type: Article

References (33)

1. American Cancer Society (2012). Cancer Facts and Figures 2012. American Cancer Society, Atlanta, GA.
2. Bennett JM, Kouides PA, and Forman SJ (2002). The myelodysplastic syndromes: morphology, risk assessment, and clinical management. Int J Hematol 2, 228-238.
3. Davies SP, Reddy H, Caivano M, and Cohen P (1999). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Curr Opin Chem Biol 351, 95-105.
4. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, and Vande Woude GF (2002). Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci USA 99, 3052-3057.
5. Abi-Habib RJ, Urieto JO, Liu SH, Leppla SH, Duesbery NS, and Frankel AE (2005). Braf status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 4, 1303-1310.
6. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, and Marais R (2004). V599EB-Raf is an oncogene in melanocytes. Cancer Res 64, 2338-2342.
7. Lee JT Jr and McCubrey JA (2002). The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 16, 486-507.
8. Hilger RA, Scheulen ME, and Strumberg D (2002). The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25, 511-518.
9. Wu J, Wong WW, Khosravi F, Minden MD, and Penn LZ (2004). Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64, 6461-6468.
10. Milella M, Kornblau S, Estrov Z, Carter B, Lapillonne H, Konopleva M, Zhao S, Estey E, and Andreef M (2001). Therapeutic targeting of the Mek/ Mapk signal transduction module in acute myeloid leukemia. J Clin Invest 108, 851-859.
11. Bradley KA, Mogridge J, Mourez M, Collier RJ, and Young JA (2001). Identification of the cellular receptor for anthrax toxin. Nature 414, 225-229.
12. Scobie HM, Rainey JA, Bradley KA, and Young JA (2003). Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA 100, 5170-5174.
13. Abrami L, Liu S, Cosson P, Leppla SH, and Van der Goot FG (2003). Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrindependent process. J Cell Biol 160, 321-328.
14. Abrami L, Leppla SH, and Van der Goot FG (2006). Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis. J Cell Biol 172, 309-320.
15. Melnyk PA and Collier RJ (2006). A loop network within the anthrax toxin pore positions the phenylalanine clamp in an active conformation. Proc Natl Acad Sci USA 103, 9802-9807.
16. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paul KD, et al. (1998). Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280, 734-737.
17. Chopra AP, Boone SA, Liang X, and Duesbery NS (2003). Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J Biol Chem 278, 9402-9406.
18. Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS, and Frankel AE (2006). Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clin Cancer Res 12, 7437-7443.
19. Zaidi SK, Dowdy CR, van Wijnen AJ, Lian JB, Raza A, Stein JL, Croce CM, and Stein GS (2009). Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network. Cancer Res 69, 8249-8255.
20. Ricciardi M, Scerpa M, Bergamo P, Ciuffreda L, Petrucci M, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, et al. (2012). Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. J Mol Med (Berl) 90(10), 1133-1144.
21. Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M, and Ruvolo PP (2005). The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19, 1350-1354.
22. Ramirez DM, Leppla SH, Schneerson R, and Shiloach J (2002). Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J Ind Microbiol Biotechnol 28, 232-238.
23. Liu S, Bugge TH, and Leppla SH (2001). Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 276, 17976-17984.
24. Ramage J, Vallera DA, Black J, Aplan P, Kees U, and Frankel AE (2003). The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leuk Res 27, 79-84.
25. Bardet V, Tamburini J, Ifrah N, Dreyfus F, Mayeux P, Bouscary D, and Lacombe C (2006). Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica 91, 757-764.
26. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, et al. (2012). The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18, 2316-2325.
27. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, and Evers BM (2012). PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res 176, 542-548.
28. Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, and Newell DR (2012). The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106, 1386-1394.
29. Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A, et al. (2012). Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther 11, 1193-1202.
30. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, and Stegmeier F (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69, 4286-4293.
31. James JA, Smith MA, Court EL, Yip C, Ching Y, Willson C, and Smith JG (2003). An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia. Hematol J 4, 427-432.
32. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, et al. (2002). Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/ MAPK pathways in acute myelogenous leukemia. Blood 99, 3461-3464.
33. Morgan MA, Dolp O, and Reuter CW (2001). Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 97, 1823-1834.